Yeast genes that affect viral replication
AssigneeWisconsin Alumni Research Foundation
InventorsPaul G. Ahlquist, Masayuki Ishikawa, Juana Diez, Duane B. Price, Wai-Ming Lee
Life of this patent
Estimating the term…
Abstract
An antiviral agent comprising an altered MAB1, MAB2, MAB3, or OLE1 gene, gene homologs or related genes is disclosed. In another embodiment, the present invention is a method of creating a virus resistant organism comprising creating a transgenic organism comprising an antiviral agent selected from the group of altered MAB1 genes, MAB2 genes, MAB3 genes or OLE1 genes, homologs of these genes, related genes and combinations of these genes and homologs.
Claims4
A method of evaluating a substance as a positive strand RNA antiviral agent, comprising the steps of
- a) exposing a substance to a yeast or mammalian Δ9 fatty acid desaturase enzyme, and
- b) evaluating the effect of the substance on the stability of the enzyme, wherein decrease in stability indicates that the substance is an antiviral agent against positive strand RNA virus.
A method of evaluating a substance as a positive strand RNA antiviral agent, comprising the steps of
- a) exposing a substance to a yeast or mammalian Δ9 fatty acid desaturase enzyme, and
- b) evaluating the effect of the substance on the activity of the enzyme, wherein the inhibition of activity indicates that the substance is an antiviral agent against positive strand RNA virus.
A method of evaluating a substance as a positive strand RNA antiviral agent, comprising the steps of
- a) exposing a substance to yeast OLE1 desaturase enzyme, and
- b) evaluating the effect of the substance on the stability of the enzyme, wherein decrease in stability indicates that the substance is an antiviral agent against positive strand RNA virus.
A method of evaluating a substance as a positive strand RNA antiviral agent, comprising the steps of
- a) exposing a substance to a yeast OLE1 desaturase enzyme, and
- b) evaluating the effect of the substance on the activity of the enzyme, wherein the inhibition of activity indicates that the substance is an antiviral agent against positive strand RNA virus.
Dependencies are inferred from the claim text.